Gastroenterology 2 Inflammatory bowel disease : clinical aspects and established and evolving therapies

In clinical practice, disease activity is typically described as mild (up to four bloody stools daily and no systemic toxicity), moderate (four to six bloody stools daily and minimal toxicity), or severe more than six stools daily and signs of toxicity, such as fever, tachycardia, anaemia, raised er...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2007-05, Vol.369 (9573), p.1641-1657
Main Authors: BAUMGART, Daniel C, SANDBORN, William J
Format: Article
Language:English
Subjects:
Biological and medical sciences
Blood transfusions
Bowel disease
Clinical medicine
Clinical trials
Colorectal cancer
Crohn's disease
Drugs
Gastroenterology. Liver. Pancreas. Abdomen
General aspects
Health education
Inflammatory bowel disease
Medical sciences
Monoclonal antibodies
Other diseases. Semiology
Patients
Pharmaceutical industry
R&D
Research & development
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In clinical practice, disease activity is typically described as mild (up to four bloody stools daily and no systemic toxicity), moderate (four to six bloody stools daily and minimal toxicity), or severe more than six stools daily and signs of toxicity, such as fever, tachycardia, anaemia, raised erythiocyte sedimentation rate.1,4 Patients with fulminant ulcerau've colitis usually have mote than ten bloody stools daily, continuous bleeding, anaemia requiring blood transfusion, abdominal tenderness, and colonie dilation on plain abdominal radiographs (figure 1). AstraZeneca, Berlex, BioBalance Corporation, Boehringer-Ingelheim Inc, Bristol Meyers Squibb, Celgene, Cerimon Pharmaceuticals Inc, Centocor, ChemoCentryx Inc, CombinatoRx, Inc, Elan, FlexPharm Ltd, Glaxo Smith Kline, Genentech, Hoffman LaRoche, Inc, Human Genome Sciences, Hutchison Medipharma, Ltd, Inflabloc Pharmaceuticas (formerly Phanrodigm, Inc), Inotek Pharmaceutical Corporation, ISIS Pharmaceuticals, Jacobus Pharmaceutical Company, Johnson & Johnson Pharmaceutical Research & Development, Millennium Pharmaceuticals Inc., Nisshin Kyorin Pharmaceutical Co, Ltd, Novartis, NPS Pharmaceuticals, Otsuka America Pharmaceuticals, PDL Biopharma (formerly Protein Design Labs), Procter and Gamble Pharmaceuticals, Prometheus Laboratories, Renovia, Renovis Inc, Salix, Schering Plough, Serono, Shire Pharmaceuticals, Synta Pharmaceuticals Inc, Targacept Inc, Teva Pharmaceuticals, Therakos, UCB Pharma (formerly Celltech), Vela Pharmaceuticals, ViaCell Inc; and has participated in continuing medical educationevents indirectly sponsored by Abbott Laboratories, AstraZeneca, Centocor, Elan, Otsuka America Pharmaceuticals, PDL Biopharma (formerly Protein Design Labs), Procter and Gamble Pharmaceuticals, Prometheus Laboratories, Salix, Schering Plough, Shire Pharmaceuticals, UCB Pharma (formerly Celltech).
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(07)60751-X